Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

FDA approves Mylan's generic extended-release diltiazem

May 9, 1997

Mibefradil evaluated for impact on mortality in large CHF trial

May 8, 1997

ANDA filed for Biovail generic calcium channel blocker

May 7, 1997

Potent and selective ETA antagonists from Shionogi

May 7, 1997

Cytel and Schwarz terminate research collaboration

May 6, 1997

Results from analysis of 10 years of amiodarone therapy presented

May 6, 1997

CytRx initiates new phase II trial of purified RheothRx

May 5, 1997

Lp-PLA2 inhibitors from SmithKline Beecham

May 5, 1997

Zeneca and the University of Oxford enter collaboration for genetic research into heart disease

May 2, 1997

Calcium antagonist shown to cause left ventricular hypertrophy regression

April 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...